THE GHOST IN THE PHARMACY
WHY LIFE-SAVING DRUGS ARE OUT OF REACH IN NIGERIA, AND HOW TECHNOLOGY CAN HELP
INTRODUCTION
You leave a hospital with a prescription in your hand.
The diagnosis has been made. The treatment has been prescribed. You know what medicine you need.
But then comes a question that should be simple: Where do I get the medicine?
You call one pharmacy. It is out of stock.
You visit another. They do not carry it.
A third pharmacy tells you they had it recently, but it is no longer available.
So you keep searching.
Meanwhile, somewhere else in the city, the same medicine may already be sitting on a pharmacy shelf, in a warehouse, or somewhere within the pharmaceutical supply chain.
The medicine exists.
But for the patient who cannot find it, it can feel as though it does not.
This is the paradox at the heart of medicine access in Nigeria: a medicine can exist within the healthcare system and still remain practically out of reach for the person who needs it.
The problem is not always the complete absence of medicine. Sometimes, it is the absence of visibility, connectivity, and efficient access.
Nigeria’s medicine supply system operates across a complex network involving manufacturers, importers, regulators, distributors, wholesalers, pharmacies, healthcare facilities, and patients. Weaknesses at different points in this chain can affect the availability and accessibility of health products. [1][2]
The result is a system in which the physical existence of a medicine does not always translate into timely access for the patient.
1. THE PARADOX: EXISTING MEDICINE, MISSING CURES
Access to medicines depends on far more than whether a drug has been manufactured.
A medicine must move through a complex chain, from manufacturing or importation, through regulation, procurement, and distribution, to storage and ultimately the pharmacy where a patient can obtain it.
At every stage, there are potential bottlenecks.
Nigeria’s pharmaceutical ecosystem continues to face challenges involving supply chains, distribution, availability, affordability, regulation, and access to essential medicines.
This creates a troubling paradox: the medicine may be somewhere within the system, but the patient may have no reliable way of knowing where.
For the patient, availability is not an abstract national statistic. It is a very practical question:
“Can I get the medicine I was prescribed, safely and on time?”
If the answer is unclear, the treatment journey becomes uncertain.
2. STRUCTURAL FAILURE DRIVEN BY SYSTEMIC BOTTLENECKS
The medicine-access problem cannot be attributed to a single failure. It is driven by interconnected bottlenecks across the pharmaceutical ecosystem.
2.1 Importation and Foreign-Exchange Volatility
Nigeria’s pharmaceutical market remains exposed to international supply conditions and the cost of importing medicines and pharmaceutical inputs.
Changes in foreign exchange, importation costs, and global supply conditions can affect the affordability and availability of medicines.
When costs increase or supply becomes disrupted, the impact eventually reaches distributors, pharmacies, and patients.
These pressures make a resilient and well-coordinated supply system increasingly important. [1][5]
2.2 Fragmented and Opaque Distribution
Medicines move through multiple layers of distributors, wholesalers, pharmacies, and other stakeholders.
When information is fragmented across these different levels, it becomes difficult to determine where a particular medicine is located, how much is available, and how quickly it can reach the point of need.
A medicine may exist within the wider supply chain while remaining effectively invisible to the patient or pharmacy searching for it.
This lack of visibility can create unnecessary delays and inefficiencies. [1][2]
2.3 Counterfeit, Quality, and Regulatory Gaps
Medicine access cannot be separated from medicine quality and safety.
Patients need more than a product that is simply available. They need medicines that are authentic, properly handled, and obtained through legitimate channels.
Good distribution practices, product traceability, and effective regulatory oversight are therefore critical components of a safe pharmaceutical system. [3][4]
A medicine that is available but improperly stored, transported, or sourced cannot be considered a complete solution to the access problem.
2.4 Lack of Real-Time Inventory Visibility
This is one of the most practical gaps.
A pharmacy may have a medicine in stock, but a patient across town may not know.
Another pharmacy may be searching for stock that exists elsewhere but have no efficient way of identifying it.
Inventory information may remain within individual businesses rather than becoming useful information that supports better decisions across the healthcare journey.
The result is a disconnect between physical supply and accessible information.
And when information is fragmented, patients are often left to do the searching themselves.
3. WHEN PATIENTS CANNOT FIND THEIR MEDICINE
These systemic problems are not merely operational inconveniences.
For patients, delays in accessing medicines can become part of an already difficult healthcare experience.
The following cases illustrate the human cost of gaps in medicine availability, distribution, and access.
3.1 Anthony: When Time Matters
Anthony is six years old and presents with severe status asthmaticus.
He requires urgent treatment, but the hospital does not have the required medicine available.
His father begins searching.
One pharmacy does not have it. Another does not have it. He continues from one location to another until he eventually finds the medication.
But by then, Anthony’s condition has deteriorated, and he dies.
The devastating question is not simply whether the medicine existed.
The question is: Could it have been found in time?
According to the account, stock was reportedly available within a warehouse only a few kilometres away.
The medicine was somewhere within the system. But that information did not reach the person who needed it when it mattered most.
That is the difference between having supply and having visibility of supply.
3.2 Blessing: When Availability Meets Quality
Blessing is 28 and has just given birth.
She develops postpartum haemorrhage and requires urgent intervention.
The clinic’s supply situation becomes a critical problem.
A relative is sent to obtain oxytocin from outside the facility. The medicine is transported under conditions that raise concerns about temperature control and product integrity.
Again, the issue is not simply whether the medicine can be found.
It is whether the right medicine is available, obtained through a legitimate channel, and appropriately handled throughout the supply chain.
For medicines that require controlled storage conditions, availability without proper handling does not constitute reliable access.
Medicine access must therefore be concerned with both availability and quality. [3][5]
3.3 Emmanuel: When Stockouts Become a Health Problem
Emmanuel is 52 and lives with type 2 diabetes and stage 2 hypertension.
He relies on regular medication to manage his conditions.
But his usual pharmacy runs out of some of the medicines he needs.
Unable to immediately find alternatives, he begins rationing what he has and eventually misses doses.
For someone living with a chronic condition, interruptions in medication can have serious consequences.
The problem is not necessarily that the medicines do not exist. The problem is that the patient cannot reliably access them when they need them.
And that distinction matters.
Because healthcare does not end when a prescription is written.
The medicine must still reach the patient.
4. FROM RANDOM SEARCH TO REAL-TIME CERTAINTY
These situations point to a larger problem.
Patients should not have to rely entirely on trial and error to find prescribed medicines.
Calling one pharmacy after another, travelling from location to location, and repeatedly asking whether a medicine is available is an inefficient way to navigate healthcare.
The system needs stronger connections between:
- Patient demand
- Pharmacy inventory
- Verified medicine availability
- Distribution
- Fulfilment
This does not mean technology can solve every problem in Nigeria’s pharmaceutical supply chain.
It cannot manufacture medicines that do not exist.
It cannot eliminate foreign-exchange pressures.
It cannot replace pharmaceutical regulation.
It cannot solve every distribution or infrastructure challenge.
But technology can address something extremely important: uncertainty.
It can help make information more visible.
It can help pharmacies manage what they have.
It can help patients discover where medicines may be available.
And it can help connect different parts of the medicine-access journey.
5. THE ROLE OF STRONGREED TECHNOLOGY
This is where Strongreed’s technology ecosystem fits into the larger picture.
The objective is not to claim that one company can fix every weakness in Nigeria’s healthcare system.
The opportunity is more specific: to use technology to create better visibility, better pharmacy operations, and better connections between pharmacies and the people they serve.
Strongreed approaches this from two important sides of the ecosystem.
6. KWICKPHARM: STRENGTHENING THE PHARMACY FROM WITHIN
A pharmacy is more than a place where medicines are sold.
Behind the counter is a business that must manage inventory, sales, purchasing, records, customers, and day-to-day operations.
When these processes are poorly managed, pharmacies can struggle to maintain visibility over what they have, what is moving, and what needs attention.
KwickPharm, Strongreed’s Pharmacy Management System, is designed to help pharmacies manage these operations more effectively.
Better inventory management gives pharmacy owners greater visibility into their stock and business activity.
They can better understand what is currently available, what is moving, what is running low, what needs to be reordered, and what is happening across their pharmacy operations.
This matters because inventory visibility is not simply a business advantage.
It is part of building a more responsive pharmacy environment.
A pharmacy that knows what it has is better positioned to serve the patient who needs it.
7. EAZYMED: BRINGING THE PATIENT CLOSER TO THE MEDICINE
The patient’s problem, however, begins outside the pharmacy.
They may have a prescription but have no idea which pharmacy can fulfil it.
This is where EazyMed approaches the problem from the consumer side.
EazyMed provides a digital pathway for consumers to find prescribed medicines from verified pharmacies, place orders, and have them delivered.
Instead of beginning with the question, “Which pharmacy should I call?”, the experience can begin digitally.
The patient can search, discover available options, and place an order through a more convenient channel.
The goal is not simply to put medicine online.
The goal is to make the journey from prescription to access easier.
8. CONNECTING THE TWO SIDES
The larger opportunity lies in connecting these experiences.
On one side, the pharmacy needs better tools to manage its inventory and operations.
On the other, the patient needs a simpler way to discover and access prescribed medicines.
KwickPharm addresses the pharmacy-management side.
EazyMed addresses the consumer-access side.
Together, they represent different points within a broader healthcare technology ecosystem.
The underlying principle is simple:
“Better information can lead to better decisions, better operations, and better access.”
This is not about replacing the healthcare system.
It is about making parts of the system work better.
9. TECHNOLOGY IS NOT THE CURE-ALL, BUT IT IS PART OF THE SOLUTION
It is important to be realistic.
Technology alone cannot solve Nigeria’s medicine-access problem.
There will always be challenges involving manufacturing capacity, importation, regulation, affordability, logistics, infrastructure, and supply.
But that does not make technology irrelevant.
It makes targeted technology more important.
The objective should be to identify the gaps where technology can genuinely create value and solve those problems well.
For medicine access, one of those gaps is visibility.
If a medicine is available but nobody knows where it is, the system has a visibility problem.
If a pharmacy cannot effectively understand its inventory position, the system has an inventory-management problem.
If a patient has a prescription but cannot identify a legitimate pharmacy where the medicine is available, the system has an access problem.
These problems are connected.
And better digital infrastructure can help connect the dots.
10. FROM “WHERE CAN I FIND IT?” TO “I KNOW WHERE TO FIND IT.”
Nigeria’s medicine-access challenge is complex.
It is influenced by manufacturing, importation, foreign exchange, regulation, distribution, storage, affordability, pharmacy operations, and patient behaviour.
There is no single solution.
But there is a clear opportunity to make the system more connected and visible.
Because sometimes, the problem is not that the medicine does not exist.
The problem is that the person who needs it cannot find it.
A prescription is only the beginning of a patient’s treatment journey.
The journey is not complete until the patient can access the medicine they have been prescribed through a safe and reliable channel.
Technology cannot create every medicine Nigeria needs.
But it can help make existing supply more visible.
It can help pharmacies operate more intelligently.
It can help patients navigate the path from prescription to fulfilment with less uncertainty.
And it can help close the gap between where medicine exists and where it is needed.
The medicine may already be there.
The question is whether the person who needs it can find it.
That is the gap Strongreed is working to help close.
References
- Federal Ministry of Health (FMoH) & Department of Food and Drug Services. (2020). National Health Products Supply Chain Strategy and Implementation Plan 2021–2025. Abuja, Nigeria: Federal Ministry of Health.
- Federal Ministry of Health (FMoH) & National Product Supply Chain Management Programme (NPSCMP). (2024). National Oversight Framework for Reconciliation, Triangulation, and Accountability of Health Products. Abuja, Nigeria: Federal Ministry of Health.
- National Agency for Food and Drug Administration and Control (NAFDAC). (2021). Good Distribution Practice (GDP) Guidelines for Pharmaceutical Pro